Results 131 to 140 of about 260,886 (316)

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

A Non‐Canonical Role of SMAD4 in Regulating 3D Genome Architecture to Inhibit Lung Squamous Cell Carcinoma Development

Advanced Science, EarlyView.
SMAD4 is identified as a guardian of 3D genome architecture in lung squamous cell carcinoma. Loss of SMAD4 unleashes EP300 at chromatin loop anchors, strengthening enhancer–promoter looping and H3K27ac at the SOX2 locus to drive aberrant SOX2 activation and tumor cell proliferation.
Qian Tang, Chen Lian, Xinyan Han, Xuhan Zhang, Zihan Wang, Boyu Wang, Taoyu Zhu, Xinrui Lin, Xiaolei Wang, Yaping Xu, Manyu Xiao, Zijin Wang, Junming Li, Silin Chen, Yunze Wang, Yufei Liu, Songsong Li, Zuolin Shen, Xi Lu, Xueqi Han, Yilu Zhou, Mingyang Xiao, Jiayi Ran, Xiaoran Cao, Xinyi Xu, Hugo Sámano‐Sánchez, Alfredo Rodríguez, Lian Wang, Shuifang Chen, Zhanyu Xu, Shirong Zhang, Nuo Yang, Yong Tang, Jian Liu   +33 more
wiley   +1 more source

CircEPSTI1 Promotes the Progression of Non-Small Cell Lung Cancer Through miR-145/HMGB3 Axis

Cancer Management and Research, 2020
Yuanyuan Xie,1 Li Wang,2 Danfen Yang2 1Department of Geriatrics, Affiliated Hospital of Yan’an University, Yan’an 716000, Shaanxi, People’s Republic of China; 2Department of Respiratory Medicine, Affiliated Hospital of Yan’an ...
Xie Y, Wang L, Yang D
doaj  

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source

Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells

, 2018
Yan Chen,1 Lin Zhang,1 Lei Liu,1 Shixiu Sun,2 Xuyang Zhao,1 Yueyuan Wang,2 Yujie Zhang,2,3 Jun Du,2,3 Luo Gu1–3 1Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China ...
Liu L, Zhang Y, Sun S, Gu L, Chen Y, Zhang L, Du J, Wang Y, Zhao X   +8 more
core  

A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
This study introduces a foundation model‐based biomarker for risk stratification of pathological response in non‐small cell lung cancer. A Vision Mamba super‐resolution model standardizes heterogeneous CT images. A multi‐task Swin Transformer then fine‐tunes a pre‐trained lung foundation model to jointly optimize tumor segmentation and response ...
Yanglan Xu, Shuchang Zhou, Qin Peng, Xiao Bao, Xiaodan Ye, Ahmet Görkem Er, Tong Tong, Mirabela Rusu, Yajia Gu, Mailin Chen, Jing Gong   +10 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Progress of Microsatellite (GT/CA)n Repeat Polymorphisms in Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu
Non-small cell lung cancer (NSCLC) is the most important histological type of lung cancer. This disease affects a large number of patients, and the prognosis of advanced patients is poor.
YANG Wenjun, FU Yuting, YUAN Yeqin, LIU Da, JIANG Binyuan   +4 more
doaj   +1 more source